Endoscopy News and Research

RSS

FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31

Repligen Corporation today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis.

26 Mar 2012

Boston Scientific's WallFlex Stent technology now available for interventional radiologists

Boston Scientific Corporation announces the U.S. and international launch of the WallFlex Biliary Transhepatic Stent System.

23 Mar 2012

More colonoscopy procedures under anesthesia than expected: Study

According to researchers more patients underwent general anesthesia during gastroenterological procedures such as colonoscopy between 2003 and 2009.

21 Mar 2012

Boston Scientific lauds private insurance reimbursement coverage for bronchial thermoplasty

Boston Scientific Corporation welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed using the Alair Bronchial Thermoplasty System. Minnesota-based HealthPartners and Michigan-based Priority Health recently issued the first public postings of positive insurance coverage policies providing their respective memberships with reimbursement for this novel procedure to treat severe asthma.

19 Mar 2012

Solos to introduce new endoscopic instrument line, SteriTAP

Solos Endoscopy, Inc. is pleased to announce that the Company will be launching a new endoscopic instrument line, SteriTAP.

17 Mar 2012

Endoscopic transgastric necrosectomy associated with lower risk of major complications

In a small, preliminary trial, patients with infected necrotizing pancreatitis who received a less-invasive procedure, endoscopic transgastric necrosectomy, had an associated lower risk of major complications and death compared to patients who had surgical necrosectomy, according to a study in the March 14 issue of JAMA.

14 Mar 2012

Cicel, Mazor Robotics sign agreement to distribute Renaissance system in China

Mazor Robotics Ltd, the leader in innovative surgical robots and complementary products for spine surgery, signed an agreement with Cicel Science & Technology Co., Ltd. to distribute its Renaissance system in China.

12 Mar 2012

Researchers identify genetic signature for eosinophilic esophagitis

Researchers have identified a genetic signature for a severe, often painful food allergy – eosinophilic esophagitis – that could lead to improved diagnosis and treatment for children unable to eat a wide variety of foods.

12 Mar 2012

Cantel second quarter net income increases 28% to $7,294,000

CANTEL MEDICAL CORP. reported a 28% increase in net income to a record $7,294,000, or $0.27 per diluted share, on a 20% increase in sales to a record $97,297,000 for the second quarter ended January 31, 2012.

8 Mar 2012

Make That Call campaign to promote colorectal cancer screening

Katie Couric, NewYork-Presbyterian and its Jay Monahan Center for Gastrointestinal Health, the Entertainment Industry Foundation's National Colorectal Cancer Research Alliance (NCCRA), and ABC today announced the "Make That Call" campaign to promote colon cancer screening for National Colon Cancer Awareness Month.

6 Mar 2012

FUJIFILM Synapse RIS v6.1 receives modular EHR certification for Meaningful Use for radiology

FUJIFILM Medical Systems U.S.A., Inc. today announced that Synapse RIS Version 6.1 has received modular electronic health record (EHR) certification for Meaningful Use for radiology.

5 Mar 2012

Repligen seeks EMA marketing approval for SecreFlo for pancreatic imaging

Repligen Corporation announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for SecreFlo to improve detection of pancreatic duct abnormalities in patients with pancreatitis.

5 Mar 2012

Congress urged to pass 'Removing Barriers to Colorectal Cancer Screening Act of 2012'

Colonoscopy for colorectal cancer screening saves lives, but a loophole in current Medicare law may cause patients to think twice before undergoing this vital test. Legislation introduced today seeks to ensure that colorectal cancer screening for all Medicare beneficiaries is free, as intended.

2 Mar 2012

New research report on the electrosurgical devices market

ReportsnReports adds new market research report 'Electrosurgical Devices Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018' to its store. The global electrosurgical devices market is expected to reach $1,412.8m by 2018 growing at a CAGR of 5%.

27 Feb 2012

FDA clears invendo medical's new C20 colonoscopy system

invendo medical announced today that the company received 510(k) clearance by the U.S. Food and Drug Administration of the company's new C20 colonoscopy system including the SC20 single-use colonoscope.

24 Feb 2012

FDA grants Priority Review for Repligen's SecreFlo NDA

Repligen Corporation announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the Company's new drug application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in patients with pancreatitis.

21 Feb 2012

Patients with GERD benefit from radiofrequency ablation

Heartburn. Acid reflux, GERD. They're different terms for the same type of condition - stomach acid used for digestion travels back up the esophagus, the "food pipe" that connects your throat to your stomach.

9 Feb 2012

Deep-brain stimulation of entorhinal cortex can strengthen memory

Ever gone to the movies and forgotten where you parked the car? New UCLA research may one day help you improve your memory.

9 Feb 2012

Boston Scientific launches Expect 19 Flex Endoscopic Ultrasound Aspiration Needle

Boston Scientific Corporation announces the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound (EUS) guidance for cancer diagnosis in organs adjacent to the gastrointestinal tract.

6 Feb 2012

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.

2 Feb 2012